Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dainippon Sumitomo Pharma and Takeda Pharmaceutical receive European Marketing Authorization for Latuda


Sunday, 30 Mar 2014 07:00pm EDT 

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Co Ltd:Say European Commission has granted Marketing Authorization for once-daily oral Latuda for the treatment of schizophrenia in adults.The Marketing Authorization was based on a comprehensive clinical trial program of eight studies, which included placebo and active comparators. 

Related Company News

Company Quote

1228.0
9.0 +0.74%
24 Jul 2014